Target $1.50.
Thursday, September 8, 2022
U.S. COVID vaccine market could reach $13 bln -Moderna exec
The annual U.S. COVID-19 vaccine market going forward could be in the range of $5.2 billion to $12.9 billion, depending on the price of shots and who is eligible to receive them, Moderna Inc's chief commercial officer said on Thursday.
Arpa Garay, speaking at Moderna's annual research and development event, said that range was based on price assumptions of $64 to $100 per shot.
The low end of the estimate also assumes only the high-risk population in the United States would be eligible for boosters - some 82 million people. The high end is based on all 258 million American adults being eligible for the shots, and assumes half would get them.
U.S. officials said the government's vaccine and antiviral treatment supply will run out over the next year, meaning they expect the shots to start being sold commercially at some point in 2023.
Globally, Garay said the size of the high-risk population that would be eligible for the shots is around 340 million people.
https://finance.yahoo.com/news/1-u-covid-vaccine-market-171105000.html
Palatin STarts Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis
Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis
Oral PL8177 May Provide a Safe and Tolerable Treatment Option for Ulcerative Colitis Patients
https://finance.yahoo.com/news/palatin-announces-initiation-patient-recruitment-113000337.html
CVS to enter ObamaCare market in 10 states
NJ, IL, VA, DE, NC, NV, GA, TX, MO, FL
https://finance.yahoo.com/news/aetna-cvs-health-enter-affordable-130000175.html
Relay Therapeutics drug shows promise in early trial
A daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer of the bile ducts, led to tumor shrinkage of a third or more in 15 of 17 patients with metastatic disease, the company said Wednesday.
The results were released in an abstract at the annual meeting of the European Society for Molecular Oncology, where they will be released in full on Sunday.
China health authority encourages people to stay put for National Day holidays
China's health authority is encouraging people to stay put during next month's National Day holidays and avoid travel out of their cities to reduce the spread of COVID-19, Wu Liangyou, an official at the National Health Commission, told at a news conference on Thursday.
China observes a week of holidays following its National Day on Oct. 1.
https://news.yahoo.com/china-health-authority-encourages-people-074525380.html
Alnylam: Positive Results in Phase 3 Study of Patisiran in ATTR Amyloidosis with Cardiomyopathy
- Study Results Validate the Hypothesis That TTR Silencing by an RNAi Therapeutic has the Potential to be an Effective Approach for Treating Cardiomyopathy of ATTR Amyloidosis
- Patisiran met Primary Endpoint, Demonstrating Significant Clinical Benefit on Functional Capacity (6-MWT) Compared to Placebo at Month 12
- Patisiran Also met the First Secondary Endpoint, Demonstrating Significant Clinical Benefit on Health Status and Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire, Compared to Placebo at Month 12
- Patisiran Demonstrated Encouraging Safety and Tolerability Profile in Patients with ATTR Amyloidosis with Cardiomyopathy
- Alnylam to Host Conference Call Today at 8:00 a.m. ET
Conference Call Information
Management will discuss the APOLLO-B results via conference call on Thursday, September 8, 2022, at 8:00 a.m. ET. To access the call, please register online at https://register.vevent.com/register/BI6a961cac960e44388f73484c61dc79cf. Participants are requested to register a minimum of 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same webpage for six months.
A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Company’s website approximately two hours after the event.
Subscribe to:
Posts (Atom)